Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Vascular Biogenics's 1-Year ROIIC % for the quarter that ended in Jun. 2023 was -218.17%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Vascular Biogenics's 1-Year ROIIC % or its related term are showing as below:
STU:0VB's 1-Year ROIIC % is not ranked
in the Biotechnology industry.
Industry Median: -9.3
vs STU:0VB: -218.17
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Vascular Biogenics 1-Year ROIIC % Related Terms
Vascular Biogenics 1-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Vascular Biogenics's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0VB vs MBIO, GNPX, LEXX: 1-Year ROIIC % Comparison
For the Biotechnology subindustry, Vascular Biogenics's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vascular Biogenics 1-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vascular Biogenics's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Vascular Biogenics's 1-Year ROIIC % falls into.
Vascular Biogenics's 1-Year ROIIC % for the quarter that ended in Jun. 2023 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( -15.959 (Jun. 2023) - -32.287 (Jun. 2022) )
/
( 1.513 (Jun. 2023) - 10.007 (Jun. 2022) )
=
16.328
/
-8.494
=
-192.23%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Vascular Biogenics (STU:0VB) has a 1-Year ROIIC % of -218.17 as of Jun. 2023. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Vascular Biogenics and its competitors.
Is Vascular Biogenics' 1-Year ROIIC % too high?
Vascular Biogenics' current 1-Year ROIIC % is -218.17. Overall, Vascular Biogenics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Vascular Biogenics' 1-Year ROIIC % compare to MBIO and GNPX?
Vascular Biogenics' 1-Year ROIIC % of -218.17 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Biotechnology company?
A good 1-Year ROIIC % depends on the Biotechnology industry context. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Vascular Biogenics and its competitors. Vascular Biogenics's current 1-Year ROIIC % is -218.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vascular Biogenics stock overvalued right now?
Vascular Biogenics (STU:0VB) has a current 1-Year ROIIC % of -218.17. The current 1-Year ROIIC % is -218.17. Vascular Biogenics' overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Vascular Biogenics (STU:0VB), the current 1-Year ROIIC % is -218.17 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0VB has been successfully added to your 
